Ito M, Zhao N, Zeng Z, et al. Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126[J]. Cancer Gene Ther, 2010, 17（9）：633-644.
[5]
Bessard A, Frémin C, Ezan F, et al. RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo[J]. Oncogene, 2008, 27（40）：5315-5325.
[6]
Cha JH, Choi YJ, Cha SH, et al. Allicin inhibits cell growth and induces apoptosis in U87MG human glioblastoma cells through an ERK-dependent pathway[J]. Oncol Rep, 2012, 28（1）：41-48.
[7]
Yang TY, Chang GC, Chen KC, et al. Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells[J]. Eur J Pharmacol, 2011, 663（1-3）：17-26.
[8]
Yan DM, Dai RY, Duan CY, et al. Cross-talk between PI3K/Akt and MEK/ERK pathways regulates human hepatocellular carcinoma cell cycle progression under endoplasmic reticulum stress[J]. Zhonghua Gan Zang Bing Za Zhi, 2010, 18（12）：909-914.
[9]
Zhang T, Li Y, Zhu Z, Gu M, et al. MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells[J]. Mol Pharm, 2010, 7（5）：1576-1584.
[10]
Zhang H, Li W, Sun S, et al. Inhibition of sphingosine kinase 1 suppresses proliferation of glioma cells under hypoxia by attenuating activity of extracellular signal-regulated kinase[J]. Cell Prolif, 2012, 45（2）：167-175.
[11]
Zou ZQ, Zhang LN, Wang F, et al. The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells[J]. Mol Med Rep, 2012, 5（2）：503-508.
[12]
Kwak HJ, Kim YJ, Chun KR, et al. downregulation of Spry2 by miR-21 triggers malignancy in human gliomas[J]. Oncogene, 2011, 30（21）：2433-2442.
[13]
Zheng ST, Huo Q, Tuerxun A, et al. The expression and activation of ERK/MAPK pathway in human esophageal cancer cell line EC9706[J]. Mol Biol Rep, 2011; 38（2）：865-72.
[14]
Shukla A, Hillegass JM, MacPherson MB, et al. ERK2 is essential for the growth of human epithelioid malignant mesotheliomas[J]. Int J Cancer, 2011, 129（5）：1075-1086.
[15]
Chen C, Chang YC, Lan MS, et al. Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ ERK1/2 and PI3K/Akt signaling pathways[J]. Int J Oncol, 2013, 42（3）：1113-1119.
[16]
Burova EB, Smirnova IS, Gonchar IV, et al. Inhibition of the EGF receptor and ERK1/2 signaling pathways rescues the human epidermoid carcinoma A431 cells from IFNγ-induced apoptosis[J]. Cell Cycle, 2011, 10（13）：2197-2205.
[17]
Tong JS, Zhang QH, Huang X, et al. Icaritin causes sustained ERK1/2 activation and induces apoptosis in human endometrial cancer cells[J]. PLoS One, 2011, 6（3）：e16781.
[18]
Dai R, Chen R, Li H. Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells[J]. Int J Oncol, 2009, 34（6）：1749-1757
[19]
Li X, Lv Y, Yuan A, et al. Gastrin-releasing peptide promotes the growth of HepG2 cells via EGFR-independent ERK1/2 activation[J]. Oncol Rep, 2010, 24（2）：441-448.
[20]
Glassmann A, Reichmann K, Scheffler B, et al. Pharmacological targeting of the constitutively activated MEK/MAPK-dependent signaling pathway in glioma cells inhibits cell proliferation and migration[J]. Int J Oncol, 2011, 39（6）：1567-1575.
[21]
Sabatel C, Malvaux L, Bovy N, et al. MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells[J]. PLoS One, 2011, 6（2）：e16979.
[22]
Huang TH, Wu F, Loeb GB, et al. Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion[J]. J Biol Chem, 2009, 284（27）：18515-18524.
